Maze Therapeutics, Inc. (MAZE) earnings date
Mar 29, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 21 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | after close | 42 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | after close | 42 | 8-K |
| Q4 FY2025 | Wed, Mar 25, 2026 | before open | 84 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | after close | 43 | 8-K |
| Q1 FY2025 | Wed, May 14, 2025 | after close | 44 | 8-K |
| Q4 FY2024 | Mon, Mar 31, 2025 | before open | 90 | 8-K |
What they guided beta
| Q3 FY2026 | "Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $477 million in cash, cash equivalents and marketable securities as of September 30, 2026 supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., November 9, 2026 (GLOBE NEWSWIRE) – Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision med" exhibit |
| Q3 FY2026 | "In early 2027, Maze expects to announce the final data from HORIZON which is designed to evaluate the potential of MZE829 to treat each of three AMKD patient subgroups: AMKD without diabetes, AMKD with diabetes and AMKD with focal segmental glomerulosclerosis (FSGS)." exhibit |
| Q3 FY2026 | "Topline data from the trial is expected in 2027." exhibit |
| Q3 FY2026 | "Maze expects that its current cash, cash equivalents and marketable securities will fund operations into 2029 based on its current business plan." exhibit |
| Q2 FY2026 | "Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., August 11, 2026 (GLOBE NEWSWIRE) – Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicine" exhibit |
| Q2 FY2026 | "“The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in 2027, and continued strong enrollment in the Phase 2 HORIZON trial of MZE829 across three cohorts with additional data on track for 10-15 patients per cohort in late 2026 or early 2027,” said Jason Coloma, Ph.D., chief executive officer of Maze." exhibit |
| Q2 FY2026 | "With a strong balance sheet and expected cash runway into 2029, we are well positioned to execute against the clinical milestones in our pipeline.”" exhibit |
| Q2 FY2026 | "Maze continues to enroll the HORIZON trial, and expects to announce updated data in late 2026 or early 2027 on three 10-15 patient cohorts: AMKD without diabetes, AMKD with diabetes and AMKD with severe focal segmental glomerulosclerosis (FSGS)." exhibit |
| Q2 FY2026 | "Topline data from the trial is expected in 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MAZE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MAZE
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/MAZE/"><img src="https://veritasdata.dev/embed/MAZE.svg" alt="MAZE earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/MAZE/)
Script
<script async src="https://veritasdata.dev/embed/MAZE.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MAZE"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.